193473-82-4Relevant academic research and scientific papers
Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)
Miller, William H.,Seefeld, Mark A.,Newlander, Kenneth A.,Uzinskas, Irene N.,Burgess, Walter J.,Heerding, Dirk A.,Yuan, Catherine C. K.,Head, Martha S.,Payne, David J.,Rittenhouse, Stephen F.,Moore, Terrance D.,Pearson, Stewart C.,Berry, Valerie,DeWolf Jr., Walter E.,Keller, Paul M.,Polizzi, Brian J.,Qiu, Xiayang,Janson, Cheryl A.,Huffman, William F.
, p. 3246 - 3256 (2007/10/03)
Bacterial enoyl-ACP reductase (FabI) catalyzes the final step in each cycle of bacterial fatty acid biosynthesis and is an attractive target for the development of new antibacterial agents. Our efforts to identify potent, selective FabI inhibitors began w
Enantiospecific synthesis of SB 214857, a potent, orally active, nonpeptide fibrinogen receptor antagonist
Miller, William H.,Ku, Thomas W.,Ali, Fadia E.,Bondinell, William E.,Calvo, Raul R.,Davis, Larry D.,Erhard, Karl F.,Hall, Leon B.,Huffman, William F.,Keenan, Richard M.,Kwon, Chet,Newlander, Kenneth A.,Ross, Stephen T.,Samanen, James M.,Takata, Dennis T.,Yuan, Chuan-Kui
, p. 9433 - 9436 (2007/10/02)
An enantiospecific synthesis of SB 214857, a potent, nonpeptide fibrinogen receptor antagonist, is reported. The synthetic route employs as a key step an intramolecular aryl fluoride displacement to form the seven-membered ring of the 1,4-benzodiazepine s
